Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilio Bria

Showing results (311-320 of 377) with videos related to

Pageof 38
Sort By:
NPJ Breast Cancer|December 13, 2025
Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancerEmma Zattarin, Antonio Marra, Antonella Palazzo, et al.
Future Oncology (London, England)|June 14, 2025
Predictive risk factors of recurrence in breast cancer after neoadjuvant treatment: the NEORISK studyFranco Antonio, Luisa Carbognin, Ida Paris, et al.
NPJ Breast Cancer|August 16, 2025
Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2- metastatic breast cancer: a retrospective multi-institutional Consortium analysisLetizia Pontolillo, Andrew A Davis, Lorenzo Gerratana, et al.
Journal of the National Cancer Institute|March 28, 2026
Temporal Patterns and Factors Associated with Early Termination in Phase 1 Clinical Trials for Solid TumorsGiovanni Maria Iannantuono, Stefano Sganga, Tommaso Giovagnoli, et al.
Oncogene|August 13, 2022
Loss of FGFR4 promotes the malignant phenotype of PDACSabrina D'Agosto, Francesco Pezzini, Lisa Veghini, et al.
Breast (Edinburgh, Scotland)|May 29, 2026
Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER studyLetizia Pontolillo, Elisabetta Munzone, Paolo Vigneri, et al.
Journal of Cachexia, Sarcopenia and Muscle|October 23, 2024
Body composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational studyIlaria Trestini, Lorenzo Belluomini, Alessandra Dodi, et al.
JCO Precision Oncology|October 7, 2024
Impact of Comprehensive Genome Profiling on the Management of Advanced Non-Small Cell Lung Cancer: Preliminary Results From the Lung Cancer Cohort of the FPG500 ProgramAntonio Vitale, Luca Mastrantoni, Jacopo Russo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 17, 2019
Crizotinib in <i>MET</i>-Deregulated or <i>ROS1</i>-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms TrialLorenza Landi, Rita Chiari, Marcello Tiseo, et al.
Clinical Lung Cancer|June 25, 2017
Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE StudySara Pilotto, Antonio Rossi, Tiziana Vavalà, et al.
Pageof 38

Showing results (311-320 of 377) with videos related to

Sort By:
Pageof 38
NPJ Breast Cancer|December 13, 2025
Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancerEmma Zattarin, Antonio Marra, Antonella Palazzo, et al.
Future Oncology (London, England)|June 14, 2025
Predictive risk factors of recurrence in breast cancer after neoadjuvant treatment: the NEORISK studyFranco Antonio, Luisa Carbognin, Ida Paris, et al.
NPJ Breast Cancer|August 16, 2025
Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2- metastatic breast cancer: a retrospective multi-institutional Consortium analysisLetizia Pontolillo, Andrew A Davis, Lorenzo Gerratana, et al.
Journal of the National Cancer Institute|March 28, 2026
Temporal Patterns and Factors Associated with Early Termination in Phase 1 Clinical Trials for Solid TumorsGiovanni Maria Iannantuono, Stefano Sganga, Tommaso Giovagnoli, et al.
Oncogene|August 13, 2022
Loss of FGFR4 promotes the malignant phenotype of PDACSabrina D'Agosto, Francesco Pezzini, Lisa Veghini, et al.
Breast (Edinburgh, Scotland)|May 29, 2026
Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER studyLetizia Pontolillo, Elisabetta Munzone, Paolo Vigneri, et al.
Journal of Cachexia, Sarcopenia and Muscle|October 23, 2024
Body composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational studyIlaria Trestini, Lorenzo Belluomini, Alessandra Dodi, et al.
JCO Precision Oncology|October 7, 2024
Impact of Comprehensive Genome Profiling on the Management of Advanced Non-Small Cell Lung Cancer: Preliminary Results From the Lung Cancer Cohort of the FPG500 ProgramAntonio Vitale, Luca Mastrantoni, Jacopo Russo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 17, 2019
Crizotinib in <i>MET</i>-Deregulated or <i>ROS1</i>-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms TrialLorenza Landi, Rita Chiari, Marcello Tiseo, et al.
Clinical Lung Cancer|June 25, 2017
Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE StudySara Pilotto, Antonio Rossi, Tiziana Vavalà, et al.
Pageof 38